Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly
Personalization and Dose Adjustment With PlexusDx Your dose may need to go upand at PlexusDx, your price won't
Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine
The results revealed study participants with early signs of macular degeneration who took a modification of the original nutritional supplement that contained 10 mg lutein and 2 mg zeaxanthin (and no beta-carotene) every day for the 5-year study period had a 10 to 25 percent reduced risk of AMD progression
Medicine isnt cheating
For years, it was all about diet, exercise and lifestyle